[go: up one dir, main page]

DK1471974T3 - Tumornekrose-faktor kombineret med interferon ved demyeliniserende sygdomme - Google Patents

Tumornekrose-faktor kombineret med interferon ved demyeliniserende sygdomme

Info

Publication number
DK1471974T3
DK1471974T3 DK03737332T DK03737332T DK1471974T3 DK 1471974 T3 DK1471974 T3 DK 1471974T3 DK 03737332 T DK03737332 T DK 03737332T DK 03737332 T DK03737332 T DK 03737332T DK 1471974 T3 DK1471974 T3 DK 1471974T3
Authority
DK
Denmark
Prior art keywords
interferon
necrosis factor
tumor necrosis
demyelinating diseases
factor combined
Prior art date
Application number
DK03737332T
Other languages
Danish (da)
English (en)
Inventor
Luca Giampiero De
Original Assignee
Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading Sa filed Critical Ares Trading Sa
Application granted granted Critical
Publication of DK1471974T3 publication Critical patent/DK1471974T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK03737332T 2002-02-06 2003-01-29 Tumornekrose-faktor kombineret med interferon ved demyeliniserende sygdomme DK1471974T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02100110 2002-02-06
PCT/EP2003/050006 WO2003066165A1 (fr) 2002-02-06 2003-01-29 Facteur de necrose de tumeurs combine a un interferon dans le traitement de maladies demyelinisantes

Publications (1)

Publication Number Publication Date
DK1471974T3 true DK1471974T3 (da) 2007-12-03

Family

ID=27675735

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03737332T DK1471974T3 (da) 2002-02-06 2003-01-29 Tumornekrose-faktor kombineret med interferon ved demyeliniserende sygdomme

Country Status (14)

Country Link
US (1) US7674453B2 (fr)
EP (1) EP1471974B1 (fr)
JP (1) JP4490104B2 (fr)
AT (1) ATE373503T1 (fr)
AU (1) AU2003209755B2 (fr)
CA (1) CA2471586A1 (fr)
CY (1) CY1106999T1 (fr)
DE (1) DE60316407T2 (fr)
DK (1) DK1471974T3 (fr)
ES (1) ES2289303T3 (fr)
IL (1) IL163207A (fr)
PT (1) PT1471974E (fr)
SI (1) SI1471974T1 (fr)
WO (1) WO2003066165A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007133373A2 (fr) * 2006-05-01 2007-11-22 England Robert L VACCIN CONTRE LE TNF-α POUR LE TRAITEMENT D'ÉTATS PATHOLOGIQUES À MÉDIATION ASSURÉE PAR LE TNF-α PATHOLOGIQUE
HK1213794A1 (zh) * 2012-10-09 2016-07-15 Biogen Ma Inc. 联合治疗及用於治疗脱髓鞘病症的用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3423234A1 (de) * 1984-06-23 1986-02-06 Boehringer Ingelheim International GmbH, 6507 Ingelheim Synergistische mischungen von interferonen und tumor-nekrose-faktor
DE3663374D1 (en) * 1985-12-09 1989-06-22 Picanol Nv Process for unwinding a thread from a reel in looms, and arrangement used therefor
CA1290249C (fr) 1986-04-09 1991-10-08 Cetus Corporation TRAITEMENT A BASE D'INTERLEUKINE-2 ET (OU) D'INTERFERON .beta. ET FACTEUR DE NECROSE TUMORALE
US5098702A (en) * 1986-04-09 1992-03-24 Cetus Corporation Combination therapy using interleukin-2 and tumor necrosis factor
IL98078A0 (en) 1991-05-07 1992-06-21 Yeda Res & Dev Pharmaceutical compositions comprising an anticytokyne
WO1992007578A1 (fr) * 1990-10-25 1992-05-14 Genentech, Inc. Utilisation d'agents protecteurs contre des especes d'oxygene reactives
CA2195665A1 (fr) 1994-07-22 1996-02-08 Robert Frederick Geoffrey Booth Compositions pharmaceutiques comprenant une proteine chimere liant le facteur de necrose tumorale
IL112834A (en) * 1995-03-01 2000-12-06 Yeda Res & Dev Pharmaceutical compositions for controlled release of soluble receptors
DK0839046T3 (da) * 1995-07-14 2002-02-18 Applied Research Systems TNF-receptor og steroidhormon i en kombinationsterapi
US6013253A (en) * 1997-08-15 2000-01-11 Amgen, Inc. Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
CA2306733A1 (fr) * 1997-10-28 1999-05-06 American Home Products Corporation Compositions et procedes d'apport de materiel genetique
US6110929A (en) * 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
ES2265693T3 (es) * 1998-10-16 2007-02-16 Biogen Idec Ma Inc. Proteinas de fusion con interferon-beta y usos.
EP1173549B1 (fr) * 1999-05-05 2008-08-13 University Of Southern California Utilisation de cytokines et de mitogenes pour empecher des reponses immunitaires pathologiques
DE60021760T2 (de) * 1999-12-09 2006-06-08 Chiron Corp., Emeryville Verfahren zur verabreichung von wirkstoffen in das zentrale nervensystem oder lymphsystem
ATE336514T1 (de) * 2000-02-11 2006-09-15 Merck Patent Gmbh Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
IT1317835B1 (it) 2000-02-15 2003-07-15 San Raffaele Centro Fond Citochine modificate per uso nella terapia del cancro.
MXPA02008023A (es) 2000-02-18 2005-06-30 Yeda Res & Dev Formulaciones de copolimero 1 para dosificacion oral, nasal y pulmonar.

Also Published As

Publication number Publication date
IL163207A (en) 2010-06-30
JP4490104B2 (ja) 2010-06-23
JP2005522434A (ja) 2005-07-28
US20050142100A1 (en) 2005-06-30
DE60316407D1 (de) 2007-10-31
ES2289303T3 (es) 2008-02-01
ATE373503T1 (de) 2007-10-15
AU2003209755B2 (en) 2007-11-22
EP1471974B1 (fr) 2007-09-19
CY1106999T1 (el) 2012-01-25
SI1471974T1 (sl) 2007-12-31
US7674453B2 (en) 2010-03-09
CA2471586A1 (fr) 2003-08-14
EP1471974A1 (fr) 2004-11-03
AU2003209755A1 (en) 2003-09-02
WO2003066165A1 (fr) 2003-08-14
PT1471974E (pt) 2007-10-12
DE60316407T2 (de) 2008-06-19

Similar Documents

Publication Publication Date Title
ATE380548T1 (de) Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie
WO2003096990A3 (fr) Cages proteiques pour l'administration d'agents therapeutiques et d'imagerie medicale
WO2004064728A3 (fr) Composes de tetracycline possedant des activites therapeutiques ciblees
WO2002074337A8 (fr) Inhibiteurs et/ou antagonistes de proteines hmgb1 destines au traitement de maladies vasculaires
WO2005078124A3 (fr) Marqueur diagnostique pour le cancer
DE602004028841D1 (de) Purin nucleoside für die behandlung von durch flavividrae verursachten krankheiten, einschliesslich hepatitis c
MY169308A (en) Treatment of tnf? related disorders
WO2004074450A3 (fr) Polytherapie pour le traitement des carences en proteines
AR045870A1 (es) Terapia de combinacion para la infeccion de virus de hepatitis c
WO2003062273A3 (fr) Traitement medical
WO2004074486A3 (fr) Proteines de fusion de muteines d'interferon-alpha aux proprietes ameliorees
IL161889A0 (en) Method for treating diseases with omega interferon
AP2004003177A0 (en) Composition and its therapeutic use
DK1471974T3 (da) Tumornekrose-faktor kombineret med interferon ved demyeliniserende sygdomme
UA83989C2 (ru) Выделенный пептид, который стимулирует противоопухолевый иммунный ответ, фармацевтическая композиция на его основе и ее применение
MXPA05008998A (es) Uso combinado de ribavirina e interferon beta en enfermedades desmielinizantes.
WO2000061176A3 (fr) Traitement combine de la sclerose en plaques
WO2003099226A3 (fr) Isomeres de position de peg d'anticorps, compositions les comprenant, et leur utilisation
WO2003080800A3 (fr) Prevention et traitement de maladies au moyen d'angiogenese et/ou d'antigenes tumoraux
WO2005123113A3 (fr) Compositions d'interferons et leurs methodes d'utilisation
MXPA03010451A (es) Nuevos metodos para el tratamiento y prevencion del dolor.
WO1999013894A3 (fr) Utilisation d'ifn-alpha et d'amantadine dans le traitement de l'hepatite c chronique
MXPA05007901A (es) Terapia de combinacion para hcv.
TW200612981A (en) Treatment of cardiomyopathy and of endothelial dysfunction
DE502004012439D1 (de) Medikament und verwendung zur tumortherapie